Powder: -20°C for 3 years | In solvent: -80°C for 1 year
COX-2-IN-34 是一种选择性的、口服有效的 COX-2 抑制剂,在小鼠实验过程中显示出抗炎活性且无胃溃疡毒性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,300 | 现货 | ||
5 mg | ¥ 2,920 | 现货 | ||
10 mg | ¥ 4,290 | 现货 | ||
25 mg | ¥ 6,890 | 现货 | ||
50 mg | ¥ 9,320 | 现货 | ||
100 mg | ¥ 12,500 | 现货 | ||
500 mg | ¥ 24,900 | 现货 |
产品描述 | COX-2-IN-34 is a selective, orally potent COX-2 inhibitor that shows anti-inflammatory activity without gastric ulcer toxicity during experiments in mice. |
靶点活性 | COX-2:0.42 μM, COX-1:34.86 μM |
体外活性 |
COX-2-IN-34 (compound 8a) (100 μM, 24 h) has no obvious cytotoxicity on RAW264.7 cells.[1] COX-2-IN-34 selectively inhibits COX-1 and COX-2 activities with IC50s of 34.86 and 0.42 μM, respectively. COX-2-IN-34 at 10 μM inhibits COX-2 by 82%.[1] |
体内活性 |
COX-2-IN-34 (compound 8a) (50 mg/kg; orally; 3 days; rats) have no gastric ulcer toxicity in a normal male rat model.[1] COX-2-IN-34 (50 mg/kg; s.c.; rats) expressed the reduction of edema claw volume after 0h, 1 h, 2 h, 3h, 4 h, and 6 h of carrageenan injection compared to the control group. Exhibited superior inhibition of 42.90% and 45.95% at the 3rd and 4th hour, respectively, which was comparatively much closer in potency to that of the Celecoxib group (45.18% inhibition of edema at 3h). Showing significant anti-inflammatory effects in the experimental model of carrageenan-induced plantar edema in rats.[1] |
分子量 | 245.23 |
分子式 | C13H11NO4 |
CAS No. | 2788578-71-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
COX-2-IN-34 2788578-71-0 Immunology/Inflammation Neuroscience COX COX2IN34 Inhibitor inhibitor inhibit